Rapid Micro Biosystems, Inc.

RPID Healthcare Medical Devices

Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS was flat and free cash flow fell 24.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

0.76 0.09 −10.59%
Market cap
$42.4M
P/E
0.0×
Fwd P/E
−2.1×
Dividend yield
—
F-score
3/9
Altman Z
−8.86
Beneish M
−5.06
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
69.95 61.17 49.23 46.26
Total non-current assets
14.46 13.68 13.14 12.19
Total Assets
84.41 74.85 62.36 58.45
Total current liabilities
16.55 18.49 19.12 18.15
Total non-current liabilities
23.53 23.16 22.85 22.55
Total liabilities
40.08 41.65 41.97 40.70
Common Equity (Total)
44.33 33.21 20.40 17.75
Shareholders Equity (Total)
44.33 33.21 20.40 17.75
Total Debt
18.83 18.90 19.05 19.14

Show all line items

In millions of $ except per-share values · columns are period end dates